Philips to Introduce Latest Advancements In Digital Pathology at the European Congress of Pathology 2020 Virtual Event

RAYUS Radiology Quality Institute Distinguished Nationally by Centers for Medicare & Medicaid

Quality Institute Again Earns Certification as Provider-Led Entity for Advanced Diagnostic Imaging Guidance to Clinicians.

LX1550 Multiparameter Remote Monitoring Platform Receives FDA 510 (k) Approval: Reports LifeSignals

Further validation of ability to deliver continuous remote patient vital signs monitoring within both hospital and home settings.

U.S. News & World Report Names Tampa General Hospital as Best in Tampa Bay

This is the sixth consecutive year that Tampa General has been named by U.S. News & World Report as Tampa Bay's top hospital.

December 4, 2020

Philips will introduce their latest advancements in digital pathology at the European Congress of Pathology 2020 virtual event, Dec. 6-8. Building on its strong portfolio to support oncology clinical decision-making, the company brings together the power of imaging, pathology, genomics, and longitudinal data with insights from artificial intelligence, to empower clinicians to deliver clear care pathways with predictable outcomes for every patient.

Pathology is vital to healthcare delivery, with 70% of decisions affecting a person’s life involving a laboratory or pathology test [1]. However, with current resource shortages, the growing volume of complex requests, and workflow inefficiencies across systems and departments, pathology labs are facing major pressures on multiple fronts.

Rather than viewing oncology as many single moments of care, Philips envisions a continuous care pathway empowered by integrated solutions for oncology and pathology that help transform and enhance multi-disciplinary workflows, including the oncology tumor board process. Critical patient data is made visible for both oncologists and pathologists, which allows them to collaborate more efficiently, to drive the right care in the right sequence at the right time.

By taking a systems view across the imaging enterprise, Philips leverages the power of smart diagnostic technologies and advanced informatics to remove the obstacles standing in the way of optimized workflows. The newly released Philips IntelliSite Pathology Solution features a leading-edge user experience (UX), enhancing the ease of use while helping streamline the imaging workflow in an automated digital solution. With this latest iteration, the company connects healthcare systems to scale digital operations and improve efficiency in high volume scanning, stimulate collaboration, and enable precision diagnosis.

Philips IntelliSite Pathology Solution offers an open, scalable, and interoperable platform that supports flexibility in deployments of image analysis software tools, strengthening Philips’s commitment to the Open Pathology platform. Other software tools allow developers and researchers to work with data natively in the iSyntax format for core research and algorithm development, enabling collaboration for education and the creation of third-party applications.

“A precise diagnosis informs the patient’s care pathway progress, from screening and diagnosis to treatment, monitoring, assessment, and the transition toward home care,” said Kees Wesdorp, Chief Business Leader Precision Diagnosis at Philips. ”Philips integrated solutions for oncology, including this latest enhancement in digital pathology, help empower the cancer care team to reach clinical treatment decisions based on richer dashboards, clinical images, reports, and structured patient data. The seamless integration of information into the oncology workflow will help improve the clinician experience and ultimately, patient outcomes.”

[1] Report of the Second Phase of the Review of NHS Pathology Services in England, Lord Carter of Coles.

spot_img

DON'T MISS

Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.